Neuro-Oncology

Article	Citations
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary	4745
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017	1162
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018	825
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019	457
EANO guideline on the diagnosis and management of meningiomas	247
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter	175
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial	153
Epidemiology of brain metastases and leptomeningeal disease	132
Fully automated hybrid approach to predict theIDHmutation status of gliomas via deep learning and radiomics	119
EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1–2 signaling	113
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas	111
The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications	111
CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018	101
Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma	101
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis	98
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial	90
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma	85
Associations of meningioma molecular subgroup and tumor recurrence	85
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR	78
Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group	77
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification	77
Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons	76
A molecularly integrated grade for meningioma	75
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors	72
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study	72

Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance	70
Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery	66
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors	66
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)	66
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults	65
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)	64
MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors	64
Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity	62
Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank	61
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma	61
Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas	61
Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas	60
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group	60
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein	59
Brain metastasis detection using machine learning: a systematic review and meta-analysis	59
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020	59
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases	58
Artificial intelligence neuropathologist for glioma classification using deep learning on hematoxylin and eosin stained slide images and molecular markers	58
Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification	58
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors	58
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design	57
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study	55
A serum-based DNA methylation assay provides accurate detection of glioma	54
Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma	53
Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes	52
The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions	52
TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT	51
MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry	51
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma	50
Synaptic input to brain tumors: clinical implications	48
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib	47
Loss of H3K27me3 in meningiomas	46
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions	46
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models	46
Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q	46
Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial	46
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylatedMGMTglioblastoma: the VERTU study	44
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas	44
Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3	43
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions	42
TGF-β promotes microtube formation in glioblastoma through thrombospondin 1	41
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas	41
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)	40
Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions	40
Extensive peritumoral edema and brain-to-tumor interface MRI features enable prediction of brain invasion in meningioma: development and validation	40
Liquid biopsy in gliomas: A RANO review and proposals for clinical applications	40
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)	40
Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics	39
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review	39
Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study	39

Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma	38
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial	38
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma	37
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma	37
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy	36
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results	36
Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study	36
Functional connectivity within glioblastoma impacts overall survival	36
MGMTpromoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review	35
An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: the IMPASSE study	35
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma	35
MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma	35
The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors	35
Establishment of patient-derived organoid models of lower-grade glioma	35
Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning	35
Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy	34
The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis	34
Cisplatin-induced peripheral neuropathy is associated with neuronal senescence-like response	34
Identification of diverse tumor endothelial cell populations in malignant glioma	33
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas	33
Management of neurofibromatosis type 1-associated plexiform neurofibromas	33
Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models	33
H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort	33
DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology	33
Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients	33
Histiocytosis and the nervous system: from diagnosis to targeted therapies	33
Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial	33
Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells	32
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus	32
The impact of socioeconomic status (SES) on cognitive outcomes following radiotherapy for pediatric brain tumors: a prospective, longitudinal trial	32
PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2	32
Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant	32
The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis	31
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid phar	30
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies	30
Corrigendum to: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017	30
DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival	30
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children’s Oncology Group study	30
Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors	29
Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO	29
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse	29
Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017	29
Newly established patient-derived organoid model of intracranial meningioma	29
The natural history of vestibular schwannoma growth—prospective 40-year data from an unselected national cohort	29
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report	29
Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors	29
The genetic landscape of choroid plexus tumors in children and adults	28
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma	28
Glioblastoma genetic drivers dictate the function of tumor-associated macrophages/microglia and responses to CSF1R inhibition	28
Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas	28
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib	27
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review	27
The use of external control data for predictions and futility interim analyses in clinical trials	27
Distinct metabolic hallmarks of WHO classified adult glioma subtypes	27
TRIM24 promotes stemness and invasiveness of glioblastoma cells via activating Sox2 expression	27
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection	27
JAM-A functions as a female microglial tumor suppressor in glioblastoma	26
Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: A longitudinal, within-patient design study	26
IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation	26
Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States	26
Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET	25
Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine	25
National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States	25
So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?	24
Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma	24
EPEN-54. ACNS0831, PHASE III RANDOMIZED TRIAL OF POST-RADIATION CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED EPENDYMOMA AGES 1 TO 21 YEARS	24
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma	24
Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a lon	24
Rapid, label-free detection of diffuse glioma recurrence using intraoperative stimulated Raman histology and deep neural networks	24
PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma	24
NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat	24
Tumor cell network integration in glioma represents a stemness feature	24
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033	24
Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors	24
TERT and DNMT1 expression predict sensitivity to decitabine in gliomas	24
Cannabidiol converts NF-κB into a tumor suppressor in glioblastoma with defined antioxidative properties	24
Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of glioblastoma	24
Randomized multi-reader evaluation of automated detection and segmentation of brain tumors in stereotactic radiosurgery with deep neural networks	23
Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma	23
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma	23

Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis	23
EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors	23
Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling	23
Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5	23
A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma	22
LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)	22
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)	22
Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging	22
Population-based estimates of survival among elderly patients with brain metastases	22
Extracellular vesicles: The key for precision medicine in glioblastoma	22
The benefit of early surgery on overall survival in incidental low-grade glioma patients: A multicenter study	22
DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma	21
Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study	21
Long-term natural history and patterns of sporadic vestibular schwannoma growth: A multi-institutional volumetric analysis of 952 patients	21
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma	21
Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts	21
Adult immuno-oncology: using past failures to inform the future	21
The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas	21
Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study	21
Inhibition of SETMAR–H3K36me2–NHEJ repair axis in residual disease cells prevents glioblastoma recurrence	21
Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles	20
Spatial concordance of DNA methylation classification in diffuse glioma	20
Relationship between genetically determined telomere length and glioma risk	20
Executive summary from American Radium Society’s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases	20
MEVITEM—a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation	20
The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3)	20
Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up	20
Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas	20
HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood–tumor barrier penetration unlinked to a passive marker	20
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study	20
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery	20
Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases	19
Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution	19
Delayed referral of pediatric brain tumors during COVID-19 pandemic	19
RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth	19
The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas	19
12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors	19
A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act	19
Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas	19
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models	18
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial	18
Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell–mediated toxicity against glioblastoma	18
CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548	18
Adult diffuse glioma GWAS by molecular subtype identifies variants inD2HGDHandFAM20C	18
Protein sumoylation with SUMO1 promoted by Pin1 in glioma stem cells augments glioblastoma malignancy	18
Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas	18
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma	18
T lymphocytes as dynamic regulators of glioma pathobiology	18
Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study	18
EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations	18
Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features	18
NEO100 enables brain delivery of blood‒brain barrier impermeable therapeutics	18
ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma	18
Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?	17
BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma	17
Development and validation of a deep-learning model for detecting brain metastases on 3D post-contrast MRI: a multi-center multi-reader evaluation study	17
SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort—A BIOMECA Consortium Study	17
Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas	17
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma	17
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy	17
Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning	17
Telomerase as a therapeutic target in glioblastoma	17
Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models	17
Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial	17
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort	17
The incidence of major subtypes of primary brain tumors in adults in England 1995-2017	16
Heterogeneity and excitability of BRAF V600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss	16
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions	16
Intellectual changes after radiation for children with brain tumors: which brain structures are most important?	16
A comparative integrated multi-omics analysis identifies CA2 as a novel target for chordoma	16
Development of a gene expression–based prognostic signature for IDH wild-type glioblastoma	16
European genetic ancestry associated with risk of childhood ependymoma	16
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma	16
Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group	16
DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients	16
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications	16
A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes	15
ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling	15
What is the burden of proof for tumor mutational burden in gliomas?	15
Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report	15
Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts	15
Sirtuin activation targets IDH-mutant tumors	15
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity	15
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival	14
EGFR, the Lazarus target for precision oncology in glioblastoma	14
Palliative care and end-of-life care in adults with malignant brain tumors	14
Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial	14
Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients	14
STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma	14
Letter regarding Louis et al: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary	14
USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5	14
Glioblastoma scRNA-seq shows treatment-induced, immune-dependent increase in mesenchymal cancer cells and structural variants in distal neural stem cells	14
Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline	14
Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease	13
Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study	13